MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • ๐Ÿ“… Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • ๐Ÿ”ง Tools
    • ๐Ÿ’ฐ Intrinsic Value Calculator
    • ๐Ÿ“ˆ Compounding Calculator
    • ๐Ÿค– Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GRFS stock logo

GRFS

Grifols, S.A.

$7.58
-0.19
 (-2.45%)
Exchange:  
Market Cap:   6.412B
Shares Outstanding:   421.254M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Jose Ignacio Abia Buenache
Full Time Employees:  23833
Address: 
Avinguda de la Generalitat, 152
Barcelona
8174
ES
Website:  https://www.grifols.com
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumย–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoringย–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Click to read more…

Revenue Segmentation

๐Ÿ”’ You are currently logged out

Login

It’s free

EPS

๐Ÿ”’ You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

๐Ÿ”’ You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

๐Ÿ”’ You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

๐Ÿ”’ You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

๐Ÿ”’ You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

๐Ÿ”’ You are currently logged out

Login

It’s free

Current Key Metrics

๐Ÿ”’ You are currently logged out

Login

It’s free

Forward P/E Ratios

๐Ÿ”’ You are currently logged out

Login

It’s free

SWOT Analysis

๐Ÿ”’ You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GRFS Intrinsic Value

Common questions about GRFS valuation

Is Grifols, S.A. (GRFS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Grifols, S.A. (GRFS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GRFS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word โ€œbuyโ€ or โ€œsellโ€ calls. Instead, it shows whether GRFS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GRFSโ€™s P/E ratio?

You can see GRFSโ€™s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GRFS?

MARKETSnap uses its own valuation frameworkโ€”not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnapโ€™s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GRFS a good long-term investment?

Whether GRFS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

๐Ÿ”’ You are currently logged out

Login

It’s free

See in Nexus

Relevant news

13-03-2026 16:41
Health Coalition demands disclosures & end to Grifols’ for-profit blood plasma contract following reports of deaths, harm, non-compliance
11-03-2026 21:36
Grifols: I’m Very Happy To Add In 2026
26-02-2026 17:27
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
08-12-2025 12:02
Grifols: Positive/Neutral Scenario Posits An Upside
27-10-2025 12:41
GRFS vs. ZTS: Which Stock Is the Better Value Option?
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • ๐Ÿ’ฐ Stock intrinsic value Calculator
  • ๐Ÿ“ˆ Investment Compounding Calculator
  • ๐Ÿค– Stock Pick Screener
  • ๐Ÿ“‹ Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read